06/01/2020



Securities and Exchange Commission
450 Fifth Street NW
Washington, DC  20549

RE:	Schedule 13G
	Progenics Pharmaceuticals, Inc.
	As of 03/31/2020

Gentlemen:

In  accordance  with  Section  13(d)(5)  of  the  Securities Exchange
Act  of  1934,  attached please  find  a  copy  of Schedule  13G/A for
the above named company showing beneficial ownership  of  5% or more
as of 03/31/2020 filed  on behalf of Eagle Asset Management,
Inc.

Very truly yours,



Damian Sousa
Vice President
Chief Compliance Officer
DS:CC
Enclosures

cc:	Office of the Corporate Secretary
	Progenics Pharmaceuticals, Inc.
	One World Trade Center, 47th Floor
	New York, NY  10007

















SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549

Schedule 13G

Under the Securities Exchange Act of 1934
(Amendment No.   4    )*

Progenics Pharmaceuticals, Inc.
(Name of Issuer)


Common Stock
(Title of Class of Securities)


743187106
(CUSIP Number)


Check the following box if a fee is being paid with this statement
_____.  (A fee is not required only if the filing person:  (1) has
a previous statement on file reporting beneficial ownership of more
than five percent of the class of securities described in Item 1;
and (2) has filed no amendment subsequent thereto reporting beneficial
ownership of five percent or less of such class.)  (See Rule 13d-7.)

*The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class
of securities, and for any subsequent amendment containing information
which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not
be deemed to be "filed" for the purpose of Section 18 of the Securities
Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of
that section of the Act but shall be subject to all other provisions of
the Act (however, see the Notes).







Page 1 of 5 Pages




CUSIP NO. 743187106	                               13G

 1  NAME OF REPORTING PERSON
    S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
      Eagle Asset Management, Inc.      59-2385219

 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*  (A) ______
                                                      (B) ______

 3  SEC USE ONLY

 4 CITIZENSHIP OR PLACE OF ORGANIZATION

   State of Florida

        NUMBER OF             5   SOLE VOTING POWER
         SHARES                           0
      BENEFICIALLY            6   SHARED VOTING POWER
         OWNED                             - - -
         AS OF
         03/31/20	     7  SOLE DISPOSITIVE POWER
        BY EACH                           0
       REPORTING              8   SHARED DISPOSITIVE POWER
      PERSON WITH                      - - -

 9  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

             0

10    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
                                                  [_____]

11  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

              0%

12  TYPE OF REPORTING PERSON*

            IA

Page 2 of 5 Pages









Item 1(a) 	Name of Issuer:

          	Progenics Pharmaceuticals, Inc.



Item 1(b) 	Address of Issuer's Principal Executing Offices:

       		One World Trade Center, 47th Floor
		New York, NY  10007




Item 2(a) 	Name of Person Filing:

         	Eagle Asset Management, Inc.


Item 2(b) 	Address of Principal Business Office:

        	880 Carillon Parkway
          	St. Petersburg, Florida  33716


Item 2(c)	Citizenship:

          	Florida


Item 2(d) 	Title of Class of Securities:

          	Common Stock


Item 2(e)	CUSIP Number:

          	743187106


Item 3    	Type of Reporting Person:

(e) Investment  Adviser  registered  under Section 203 of the Investment
Advisors Act of 1940



Page 3 of 5 Pages




Item 4   	Ownership as of 03/31/20

         (a)  	Amount Beneficially Owned:

               0 shares of common stock beneficially owned including:

                 No. of Shares
             	 Eagle Asset Management, Inc.                   0

          (b)  	Percent of Class:                              	0


         (c)	Deemed Voting Power and Disposition Power:

              	(i)            	(ii)           	    (iii)         (iv)
              	                                  Deemed          Deemed
              	Deemed         Deemed  		  to have 	  to have
              	to have        to have            Sole Power   	  Shared Power
              	Sole Power     Shared Power   	  to Dispose      to Dispose
              	to Vote or     to Vote or     	  or to           or to
              	to Direct      to Direct          Direct the      Direct the
              	to Vote        to Vote            Disposition     Disposition

Eagle Asset     0       ----     	 	 0        ----
Management, Inc.


Item 5   	Ownership of Five Percent or Less of a Class:

        	 If  this  statement is being filed to report the  fact that
as of the date hereof the reporting person has ceased to  be the  beneficial
owner of more than five percent of the  class  of securities, check the
following.
             	(X)

Item 6   	Ownership of More than Five Percent on Behalf of Another Person:

              	 N/A

Item 7   	Identification and Classification of the Subsidiary which Acquired
              	the Security Being Reported on by the Parent Holding Company:

              	 N/A

Page 4 of 5 Pages






Item 8   	Identification and Classification of  Members  of the Group:   N/A


Item 9   	Notice of Dissolution of Group:   N/A


Item 10  	Certification:

         	By  signing  below I certify that to the  best  of  my
knowledge  and  belief,  the securities referred  to  above  were acquired
in the ordinary course of business and were not acquired for  purpose  of
and  do  not have the  effect  of  changing  or influencing the control of
the issuer of such securities and were not  acquired  in  connection with
or as  a  participant  in  any transaction having such purposes or effect.

         	Signature


         After  reasonable  inquiry  and  to  the  best  of  my knowledge
and belief, I certify that the information set forth in this statement is
true, complete and correct.

Date: 06/01/20				EAGLE ASSET MANAGEMENT, INC.



 					_________________________________
 					Damian Sousa
 					Vice President
 					Chief Compliance Officer





Page 5 of 5 Pages